よむ、つかう、まなぶ。
04資料1-2 森野委員提出資料（成人用肺炎球菌ワクチンファクトシート追補版） (34 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_76211.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第36回 9／17）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
57.
Mueller PP, Tajima A, Cassell K, et al. Health and economic impact of the 21-valent pneumococcal
conjugate vaccine (V116) for adults in Japan: a delta price approach. J Med Econ 2025; 28(1): 136–45.
58.
Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of an in-development adult-formulated
pneumococcal vaccine in older US adults. Vaccine 2023; 41(30): 4431–7.
59.
Altawalbeh SM, Wateska AR, Nowalk MP, et al. Cost-effectiveness of an in-development adult-
formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older. Vaccine 2024;
42(12): 3024–32.
60.
de Boer PT, van Werkhoven CH, van Hoek AJ, et al. Higher-valency pneumococcal conjugate
vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness
study for the Netherlands. BMC Med 2024; 22(1): 69.
61.
Yi Z, Owusu-Edusei K, Elbasha E. Cost-Effectiveness Analysis of the Use of V116, a 21-Valent
Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States. Infect Dis
Ther 2024; 13(12): 2597–615.
62.
Ximenes R, Simmons AE, Gebretekle GB, et al. Cost-effectiveness analysis of 21-valent
pneumococcal conjugated vaccine among adults in Canada. Vaccine 2025; 54: 126985.
63.
Yi Z, Elbasha EH, Owusu-Edusei K. Economic evaluation of PCV21 in vaccine-naïve adults aged 19-
64 years with underlying medical conditions in the United States. J Med Econ 2025; 28(1): 665–73.
64.
Yi Z, Owusu-Edusei K, Elbasha EH. Economic evaluation of PCV21 in PCV-naïve adults aged 50-
64 years in the United States. Vaccine 2025; 59: 127264.
65.
Yi Z, Elbasha EH, Owusu-Edusei K. What About Vaccine-Experienced Younger Adults? Cost-
Effectiveness of PCV21 Use in Vaccine-Experienced US Adults Aged 19-64 Years with Underlying Medical
Conditions. Am J Prev Med 2025; 71(5): 108159.
66.
Stoecker C, Wang Y, Leidner AJ, Cho BH, Ward C, Kobayashi M. Cost-effectiveness of age-based and
risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults. Vaccine 2026; 69:
127940.
67.
Yi Z, Owusu-Edusei K, Elbasha EH. A Cost-Effectiveness Analysis of PCV21 Use in Vaccine-
Experienced Adults Aged ≥65 Years in the U.S. Am J Prev Med 2026; 71(1): 108303.
68.
Bletnitsky S, Leidner AJ, Kobayashi M, Hyun-Cho B, Stoecker C. Cost-effectiveness analysis of
expanding the adult pneumococcal vaccination recommendations to include adults aged 50 years and older in
the United States. Am J Prev Med 2026: 108412.
69.
Mueller PP, Meilleur MC, Yi Z, Martino A, Owusu-Edusei K. Cost-effectiveness analysis of the use of
PNEU-C-21 in adults aged ≥50 years in Canada. Expert Rev Vaccines 2026; 25(1): 2608811.
70.
Simuzingili M, Favre-Bulle A, Mutschler T, Yi Z, Tsoumani E, Owusu-Edusei K. Delta price cost-
effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland. J Med Econ 2026;
29(1): 334–44.
71.
Yi Z, Owusu-Edusei K, Flem E, Feemster K, Elbasha EH. Economic Evaluation of PCV21 Use in
Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction
Threshold Analysis. Infect Dis Ther 2026; 15(7): 1893–912.
34
Mueller PP, Tajima A, Cassell K, et al. Health and economic impact of the 21-valent pneumococcal
conjugate vaccine (V116) for adults in Japan: a delta price approach. J Med Econ 2025; 28(1): 136–45.
58.
Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of an in-development adult-formulated
pneumococcal vaccine in older US adults. Vaccine 2023; 41(30): 4431–7.
59.
Altawalbeh SM, Wateska AR, Nowalk MP, et al. Cost-effectiveness of an in-development adult-
formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older. Vaccine 2024;
42(12): 3024–32.
60.
de Boer PT, van Werkhoven CH, van Hoek AJ, et al. Higher-valency pneumococcal conjugate
vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness
study for the Netherlands. BMC Med 2024; 22(1): 69.
61.
Yi Z, Owusu-Edusei K, Elbasha E. Cost-Effectiveness Analysis of the Use of V116, a 21-Valent
Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States. Infect Dis
Ther 2024; 13(12): 2597–615.
62.
Ximenes R, Simmons AE, Gebretekle GB, et al. Cost-effectiveness analysis of 21-valent
pneumococcal conjugated vaccine among adults in Canada. Vaccine 2025; 54: 126985.
63.
Yi Z, Elbasha EH, Owusu-Edusei K. Economic evaluation of PCV21 in vaccine-naïve adults aged 19-
64 years with underlying medical conditions in the United States. J Med Econ 2025; 28(1): 665–73.
64.
Yi Z, Owusu-Edusei K, Elbasha EH. Economic evaluation of PCV21 in PCV-naïve adults aged 50-
64 years in the United States. Vaccine 2025; 59: 127264.
65.
Yi Z, Elbasha EH, Owusu-Edusei K. What About Vaccine-Experienced Younger Adults? Cost-
Effectiveness of PCV21 Use in Vaccine-Experienced US Adults Aged 19-64 Years with Underlying Medical
Conditions. Am J Prev Med 2025; 71(5): 108159.
66.
Stoecker C, Wang Y, Leidner AJ, Cho BH, Ward C, Kobayashi M. Cost-effectiveness of age-based and
risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults. Vaccine 2026; 69:
127940.
67.
Yi Z, Owusu-Edusei K, Elbasha EH. A Cost-Effectiveness Analysis of PCV21 Use in Vaccine-
Experienced Adults Aged ≥65 Years in the U.S. Am J Prev Med 2026; 71(1): 108303.
68.
Bletnitsky S, Leidner AJ, Kobayashi M, Hyun-Cho B, Stoecker C. Cost-effectiveness analysis of
expanding the adult pneumococcal vaccination recommendations to include adults aged 50 years and older in
the United States. Am J Prev Med 2026: 108412.
69.
Mueller PP, Meilleur MC, Yi Z, Martino A, Owusu-Edusei K. Cost-effectiveness analysis of the use of
PNEU-C-21 in adults aged ≥50 years in Canada. Expert Rev Vaccines 2026; 25(1): 2608811.
70.
Simuzingili M, Favre-Bulle A, Mutschler T, Yi Z, Tsoumani E, Owusu-Edusei K. Delta price cost-
effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland. J Med Econ 2026;
29(1): 334–44.
71.
Yi Z, Owusu-Edusei K, Flem E, Feemster K, Elbasha EH. Economic Evaluation of PCV21 Use in
Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction
Threshold Analysis. Infect Dis Ther 2026; 15(7): 1893–912.
34